Provironum Tablet is a medicine used in the treatment of male hypogonadism caused due to low testosterone levels. This medicine supplements the amount of male hormone the body produces naturally.
Provironum Tablet can be taken with or without food but it is recommended to take this medicine at the same time each day, to ensure consistent levels of the medicine in the body. Regular monitoring of prostate specific antigen (PSA) in the blood is important as this helps to track how well this medication is working. The common side effects associated with this medicine are frequent or persistent erection, acne, weight gain and gynecomastia (abnormal enlargement of breast in men).
Uses of Provironum Tablet
- Treatment of Male hypogonadism
- Treatment of Male infertility
Benefits of Provironum Tablet
Hypogonadism is the improper functioning of reproductive organs, like testes in males and ovaries in females, which causes failure to produce sex hormones required for fertility. Provironum Tablet acts as the male sex hormone, testosterone and therefore, improves sperm production in males. This can reduce infertility and helps to treat hypogonadism in males. Follow your doctor’s instructions carefully to get the most benefit.
Male infertility refers to a male’s inability to cause pregnancy in a fertile female. This may be due to inadequate amount of sex hormone in males which affects the sperm health as well as sperm count. Provironum Tablet behaves as the male sex hormone, testostrone, and helps in treating infertility in males. It improves sperm count as well as their quality. This helps proper functioing of sex organs in males and increase schances of conceiving for a female. Take it as advised by the doctor to get the most benefit.
Side effects of Provironum Tablet
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Provironum
- Limited data available
Reviews
There are no reviews yet.